Table 1.
Levels of aPL, serum immunoglobulins, d-dimer and lymphocyte subpopulations.
| Time Point | aPS/PT IgG | aPS/PT IgM | aB2GPI IgG | aB2GPI IgM | aCL IgG | aCL IgM | Total Serum IgG | Total Serum IgA | Total Serum IgM | D-Dimer | Total Lymphocyte Count | NK% | NK | CD19% | CD19 | Plasma-blasts% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day −11. Baseline | 155 | 125 | 66 | 2.1 | 85 | 8.5 | 8.8 | 0.9 | 2.1 | |||||||
| Day −7. After Plasmapheresis | 77.1 | 69.9 | 11 | 1.4 | 11 | 8.4 | 3.2 | 0.5 | 0.6 | 1418 | 6.1 | 87 | 27.4 | 389 | ||
| Day −3. After IVIG | 144 | 210 | 36 | 1.4 | 34 | 8.9 | 10.5 | 0.8 | 1 | 2028 | ||||||
| Day +4. Right after 1st dose of 8 mg/kg | 149 | 283 | 48 | 0.1 | 62 | 4.1 | 10.1 | 1.1 | 1.5 | 3497 | 1631 | 0.3 | 5 | 35.2 | 575 | 0.3 |
| Day +10. Before 2nd dose of 16 mg/kg | 113 | 179 | 33 | 0.1 | 44 | 4.3 | 7.8 | 0.5 | 0.9 | 878 | 1656 | 1.7 | 28 | 26.9 | 446 | |
| Day +17. Before 3rd dose of 16 mg/kg | 131 | 102 | 29 | 0.1 | 30 | 4.1 | 6.8 | 0.3 | 0.8 | 397 | 1728 | 0.7 | 12 | 27.2 | 470 | |
| Day +24. Before 4th dose of 16 mg/kg | 122 | 102 | 32 | 0.1 | 33 | 4.3 | 6.1 | 0.2 | 0.6 | 178 | 1660 | 0.3 | 4 | 30 | 498 | |
| Day +31. After 7 days of the end of therapy | 120 | 164 | 26 | 0.1 | 26 | 3.4 | 6.9 | 0.2 | 0.8 | 320 | 1628 | 1.2 | 20 | 29.1 | 473 | |
| Day +37. | 106 | 121 | 27 | 0.1 | 19 | 3.3 | 6.2 | 0.1 | 0.7 | 340 | 1606 | 0.8 | 12 | 24 | 386 | 0 |
| Day +79. Before 60 g IVIG | 74.2 | 134 | 25 | 1.5 | 22 | 5.4 | 4.5 | 0.1 | 0.7 | 264 | 3116 | 3.4 | 108 | 15.2 | 475 | 0 |
| Day +108. 29 days after IVIG | 82.2 | 204 | 22 | 1.6 | 18 | 5 | 11.5 | 0.1 | 1.1 | 610 | 2189 | 2.6 | 58 | 20.1 | 439 | 0.1 |
| Day +135 | 79.6 | 112 | 33 | 1.8 | 26 | 8 | 8.5 | 0.1 | 1.1 | 1280 | 3069 | 3.8 | 117 | 15.4 | 475 | |
| Day +189 | 105 | 65.5 | 36 | 1.1 | 28 | 5 | 6.6 | 0.2 | 1.2 | 201 | 2500 | 3.9 | 98 | 14.4 | 362 | |
| Day +248 | 56.1 | 63.1 | 55 | 0.1 | 53 | 8.1 | 6.8 | 0.3 | 1.5 | 563 | 2003 | 4.7 | 95 | 16 | 320 | 0.6 |
| Day +398 | 146 | 69.7 | 54 | 0.1 | 71 | 8 | 5.9 | 0.4 | 1.9 | 1855 | 2330 | 4.4 | 101 | 19 | 442 | |
| Day +593 | 169 | 58.1 | 83 | 0.1 | 70 | 8.5 | 5.7 | 0.4 | 1.4 | 2348 | 2541 | 2.9 | 74 | 27.7 | 704 |
Bold values represent the lowest levels achieved for every parameter. Besides aPL levels variation, which is described in Figure 1 , all serum immunoglobulins were affected after treatment with daratumumab, with IgG showcasing the most relevant decline. D-dimer also lowered after treatment and then went up again from day +79 until today. Total lymphocyte count did not change. NK cells and plasmablasts were practically removed from peripheral blood since the first infusion of daratumumab until day +79. aPL are expressed in U/mL. Total serum Immunoglobulins are expressed in g/L and D-dimer in mg/dL. Lymphocyte subpopulations are expressed as % of total lymphocytes or in counts/mL.